Active substance
Results for the substance bimekizumab
2 results
About this active substance
Bimekizumab is a monoclonal antibody used for the treatment of moderate to severe plaque psoriasis in adults. It works by inhibiting interleukins IL-17A and IL-17F, which play a key role in the inflammation associated with psoriasis.
The medication is administered as a subcutaneous injection, usually once every few weeks, as directed by a doctor. Treatment can lead to a significant reduction in symptoms, including psoriatic plaques and itching.
Common side effects include upper respiratory tract infections, headaches, and injection site reactions. In rare cases, more serious infections or severe allergic reactions may occur. It is important for patients to be monitored during treatment.
Bimekizumab is not recommended for pregnant or breastfeeding women unless the benefits outweigh the risks. Patients should inform their doctor of their full medical history and any other medications being used to ensure treatment safety.
The medication is administered as a subcutaneous injection, usually once every few weeks, as directed by a doctor. Treatment can lead to a significant reduction in symptoms, including psoriatic plaques and itching.
Common side effects include upper respiratory tract infections, headaches, and injection site reactions. In rare cases, more serious infections or severe allergic reactions may occur. It is important for patients to be monitored during treatment.
Bimekizumab is not recommended for pregnant or breastfeeding women unless the benefits outweigh the risks. Patients should inform their doctor of their full medical history and any other medications being used to ensure treatment safety.
-
-
BIMZELX 320mg 320mg/2ml solution for injection in pre-filled pen UCB ORIGINAL MEDICINE